| Literature DB >> 29416696 |
Qing-Zeng Qian1, Xiang-Ke Cao2, Hai-Yan Liu1, Guo-Ying Zheng1, Qing-Qiang Qian3, Fu-Hai Shen1.
Abstract
We explored the role of TNFR/TNF-α signalingin apoptosis among alveolar macrophages (AM) and its relevance to the development of coal workers' pneumoconiosis (CWP). Purified alveolar macrophages (AMs) were prepared from bronchoalveolar lavage fluid harvested from 366 CWP patients and 120 healthy subjects enrolled inthe study. The purified AMs were then divided into control, SOD, anti-TNFR, TNFR and NFkB inhibitor groups and analyzed for apoptosis usingflow cytometry (sub-diploid peak) and western blotting (Bcl-2, Caspase-3 and Caspase-8 expression). We found thatAM apoptosis washigher amongCWP patients than thehealthycontrols. Expression ofBcl-2, Caspase-3 and Caspase-8 was higher inAMs from CWP patientsthan in those from the controlsand correlated with increased AM apoptosis. Univariate and multivariate analyses suggested that CWP grade, initial exposure time, exposure time inyears, and CWP onset agewereall associated with altered levels of Bcl-2, Caspase-3 and Caspase-8. Inhibition of TNFR/TNF-α signaling usinganti-TNFR antibody, SOD or NFkB inhibitionreduced AM apoptosisand decreased Bcl-2, Caspase-3 and Caspase-8 expression. These data suggestinhibition of a TNFR/TNF-α signaling pathway is a potentiallyeffective means ofalleviating CWP by inhibiting AM apoptosis.Entities:
Keywords: alveolar macrophages; apoptosis; coal mixture workers; coal workers' pneumoconiosis; cumulative dust exposure
Year: 2017 PMID: 29416696 PMCID: PMC5787440 DOI: 10.18632/oncotarget.18921
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Comparisons in smoking rate, pulmonary function and pulmonary function indexes between the case group and the control group
| Group | Exposed group ( | Control group ( | χ2/ | |
|---|---|---|---|---|
| Age (year) | 47.80 ± 9.20 (24∼65) | 48.20 ± 8.40 (28∼68) | 0.422 | 0.673 |
| Weight (kg) | 57.70 ± 10.30 (42∼86) | 56.80 ± 10.50 (43∼85) | 0.409 | 0.827 |
| Smoking distribution | 0.462 | 0.645 | ||
| Non-smoking | 165 (45.08%) | 57 (47,50%) | ||
| Smoking | 201 (54.92%) | 63 (52.50%) | ||
| Initial working time | 21.10 ± 4.16 | 22.00 ± 5.50 | 1.890 | 0.059 |
| Work years | 23.50 ± 5.85 | 24.34 ± 6.78 | 1.311 | 0.191 |
| Retirement period | 3.83 ± 1.11 | 4.05 ± 1.06 | 1.905 | 0.057 |
Note: Initial working time, the starting age of workers exposed to dust; work years, the length of the time employed; retirement period, the duration after stopping dust exposure of workers exposed to dust.
Figure 1Representative H&E stained photographs of alveolar macrophages undergoing apoptosis as observed underlight microscope (1000×)
(A) Alveolar macrophages from normal controls; (B) Apoptotic alveolar macrophages from CWP patients.
Figure 2Flow cytometry analysis of apoptoticalveolar macrophages cells showing the sub-diploid (sub-G0/G1) peak
(A) FACS plots showing normal peaks forcontrol alveolar macrophages; (B) FACS plot showing sub-diploidpeak representing alveolar macrophages undergoing apoptosis.
Comparisons of alveolar macrophages apoptosis among different subgroups based on age, smoking, initial working time, occupational time, and working age for occurrence in the exposed group
| Group | N | Apoptotic index | χ2/ | |
|---|---|---|---|---|
| Age | 0.597 | 0.551 | ||
| < 40 | 156 | 27.22 ± 5.47 | ||
| ≥ 40 | 210 | 26.88 ± 5.25 | ||
| Smoking (duration time, years) | ||||
| 0 | 165 | 26.52 ± 5.40 | 1.876 | 0.155 |
| < 30 | 88 | 26.28 ± 5.07 | ||
| ≥ 30 | 113 | 27.62 ± 5.89 | ||
| Initial working time (years) | 0.791 | 0.429 | ||
| < 20 | 144 | 26.69 ± 5.44 | ||
| ≥ 20 | 222 | 27.18 ± 6.00 | ||
| Work years (years) | 12.290 | < 0.001 | ||
| < 20 | 170 | 23.02 ± 5.12 | ||
| ≥ 20 | 196 | 29.98 ± 6.12 | ||
| Working age for occurrence | 1.403 | 0.161 | ||
| < 10 | 130 | 27.33 ± 5.85 | ||
| ≥ 10 | 136 | 26.48 ± 5.48 |
Comparisons of the expression levels of Bcl-2, Caspase-3 and Caspase-8 in the exposed group
| Group | Case group | Control group | χ2/ | |
|---|---|---|---|---|
| Bcl-2 | 0.291 ± 0.044 | 0.211 ± 0.038 | 17.850 | < 0.001 |
| Caspase-3 | 0.338 ± 0.050 | 0.267 ± 0.040 | 14.140 | < 0.001 |
| Caspase-8 | 0.237 ± 0.041 | 0.219 ± 0.034 | 3.137 | 0.002 |
Note: these results were not influenced following the adjustment for cofounders such as age, smoking history and other baseline factors.
Comparisons of the expression levels of Bcl-2, Caspase-3 and Caspase-8 among different subgroups based on age, smoking, initial working time, occupational time, and working age for occurrence in the exposed group
| Group | N | Bcl-2 | Caspase-3 | Caspase-8 |
|---|---|---|---|---|
| Age | ||||
| < 40 | 156 | 0.356 ± 0.047 | 0.354 ± 0.047 | 0.032 ± 0.045 |
| ≥ 40 | 210 | 0.310 ± 0.035* | 0.322 ± 0.042* | 0.038 ± 0.043 |
| Smoking (duration time, years) | ||||
| 0 | 165 | 0.345 ± 0.054 | 0.401 ± 0.054 | 0.376 ± 0.050 |
| < 30 | 88 | 0.336 ± 0.048 | 0.367 ± 0.041* | 0.382 ± 0.056 |
| ≥ 30 | 113 | 0.342 ± 0.043 | 0.375 ± 0.050* | 0.367 ± 0.048 |
| Initial working time (years) | ||||
| < 20 | 144 | 0.288 ± 0.043 | 0.376 ± 0.055 | 0.256 ± 0.035 |
| ≥ 20 | 222 | 0.231 ± 0.034* | 0.345 ± 0.036* | 0.218 ± 0.040* |
| Working years (years) | ||||
| < 20 | 170 | 0.288 ± 0.060 | 0.377 ± 0.062 | 0.236 ± 0.056 |
| ≥ 20 | 196 | 0.243 ± 0.051* | 0.332 ± 0.054* | 0.228 ± 0.047 |
| Working age for occurrence | ||||
| < 10 | 130 | 0.227 ± 0.057 | 0.376 ± 0.067 | 0.321 ± 0.046 |
| ≥ 10 | 136 | 0.234 ± 0.048 | 0.337 ± 0.068* | 0.327 ± 0.050 |
Note: *P < 0.05 when compared between two subgroups.
Figure 3Western blot analyses of apoptosisregulatoryproteins among the 5 experimental groups of alveolar macrophages
The 5 experimental groups are as follows: A, control group; B, SOD group; C, TNFR group; D, anti-TNFR group; E, NF-kB inhibitor group.
Comparisons of the expression levels of Bcl-2, Caspase-3 and Caspase-8 among different subgroups based on the application of different intervention approaches
| Protein | Group | SOD treatment | Group | anti-TNFR treatment | Group | NF-kB inhibitor treatment |
|---|---|---|---|---|---|---|
| Bcl-2 | ||||||
| A | 0.291 ± 0.056 | A | 0.324 ± 0.045 | A | 0.350 ± 0.044 | |
| B | 0.147 ± 0.034* | C | 0.264 ± 0.035* | C | 0.265 ± 0.040* | |
| C | 0.245 ± 0.034** | D | 0.160 ± 0.033** | E | 0.165 ± 0.031** | |
| Caspase-3 | ||||||
| A | 0.198 ± 0.024 | A | 0.231 ± 0.050 | A | 0.231 ± 0.041 | |
| B | 0.134 ± 0.030* | C | 0.224 ± 0.042 | C | 0.221 ± 0.038 | |
| C | 0.200 ± 0.037** | D | 0.154 ± 0.032** | E | 0.143 ± 0.030** | |
| Caspase-8 | ||||||
| A | 0.234 ± 0.050 | A | 0.238 ± 0.056 | A | 0.242 ± 0.042 | |
| B | 0.153 ± 0.034* | C | 0.230 ± 0.043 | C | 0.195 ± 0.034* | |
| C | 0.213 ± 0.042** | D | 0.182 ± 0.040** | E | 0.162 ± 0.027** |
Note: A, control group; B, SOD group; C, TNFR group; D, anti-TNFR group; E, NF-kB inhibitor group. *P < 0.05 when compared with group A; **P < 0.05 when compared with group B or group C.